繁體 ENG
📣 🚚 For orders below HKD500, a standard shipping fee of HKD50 will be charged on a freight-collect basis (customer pays shipping).📣 🚚
📣 🚚 Delivery take place within 3-4 business days 🚚 📣
Acorn clients are entitled to an additional 5% premium discount!
🚚 FREE SHIPPING on all orders over HK$500.🚚
VetCart will automatically donate 2.5% of your total purchase to our supported animal charities HKDR, LAP and Kirsten’s Zoo.
0

Medical Supplies

Felycin-ca1_group
Felycin-ca1_group
Felycin-ca1_group

Vet’s Prescription Needed

PRN Pharmacal

PRN Pharmacal Felycin-CA1 for (HCM) Cats

Please note that completion/delivery for this particular medication may take approximately 1 to 4 weeks due to overseas supply issues.

 

This product is supplied by Acorn Veterinary Hospital.

 

Felycin®-CA1 (sirolimus delayed-release tablets) is the first and only disease-modifying drug conditionally approved by the FDA to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). Felycin®-CA1 targets the underlying cellular growth pathways to slow down or prevent the thickening of the cat's left ventricle wall.

 

Prescription Medication Note

POMs are stored and dispensed exclusively from Acorn Veterinary Hospital under the supervision of our veterinary team.

In compliance with legal regulations, orders for this product will only be processed and delivered following a thorough review of your pet’s prescription or medical history by our veterinary professionals. Our team may reach out to you or your current veterinarian for additional information as needed.

HK$ 1,500.00
Exp:
HK$ 1,500.00

Supported file types: PNG, JPG, BMP, DOC, PDF (maximum file size: 5 MB)

Out of Stock
Felycin-ca1_group
PRN Pharmacal Felycin-CA1 for (HCM) Cats
HK$ 1,500.00
HK$ 3,600.00
HK$ 5,700.00
Feline_Vitality
VF+ Core Feline Vitality - Everyday Health for Cats
HK$ 6.00
HK$ 153.00
Felycin-ca1_group

Key Features & Benefits

  • Disease-Modifying Action: Unlike traditional medications that only treat late-stage symptoms (like fluid buildup or irregular rhythms), this drug targets the disease itself before outward symptoms appear.
  • Proven Efficacy: In clinical field trials like the RAPACAT study, treated cats showed significantly stabilized or improved heart wall measurements compared to untreated cats.
  • Convenient Regimen: Formulated as a simple, small, once-weekly oral tablet given with a meal, reducing administration stress for owners and pets.
  • Available Strengths: Commercially packaged by PRN Pharmacal in 0.4 mg (orange package), 1.2 mg (blue package), and 2.4 mg (white package) film-coated tablets.

 

Usage Guidelines & Safety

  • Exclusions: Do not use in cats with pre-existing liver disease, diabetes mellitus, systemic hypertension, or clinical congestive heart failure.
  • Side Effects: Common adverse reactions include cardiovascular shifts linked to HCM progression, lethargy, vomiting, diarrhea, and inappetence.
  • Handling Precautions: Pregnant or breastfeeding women must strictly avoid touching the medication.
  • Please consult with your veterinarian for medication dosage